Artera’s prostate cancer AI risk estimates closely tracked observed outcomes, studies report

Artera’s promise is more personalized prostate cancer treatment. Five studies presented at the 2026 American Society for Radiation Oncology meeting put parts of that promise to the test. The company reported that its AI risk estimates closely matched observed outcomes, performed consistently across demographic groups, and helped inform hormone therapy and radiation decisions.

Checking the forecast against patient outcomes

The digital pathology-based tool is called a multimodal AI biomarker, or MMAI. One analysis compared risk projections from patients tested commercially with STAR-CAP, a database containing outcomes for nearly 20,000 prostate cancer patients. It checked two distinct forecasts: cancer spreading to distant parts of the body and death specifically from prostate cancer.

In an October 9 Urology Times review, Daniel E. Spratt, MD, detailed the comparison across low-, intermediate-, and high-risk groups defined by the National Comprehensive Cancer Network. Predicted 10-year rates of distant cancer spread were 2.4%, 3.4%, and 12.9%. The observed STAR-CAP rates were 1.0%, 4.0%, and 13.5%, respectively.

Beyond the original radiation trials

MMAI was initially validated in randomized trials involving radiation, with or without hormone therapy. Most STAR-CAP patients instead underwent surgery. Spratt said the forecasts remained well calibrated—meaning predicted risks closely matched observed outcomes—in this mixed surgery and radiation cohort.

An analysis of NRG/RTOG phase 3 trials after prostate removal found consistent prognostic accuracy across racial and age subgroups. Clinical Lab Products, describing Artera’s findings, reported no evidence of algorithmic bias in that analysis—not universal freedom from bias.

A gene-expression study offered a biological cross-check. Among approximately 90 patients from native African, African American, and European American cohorts, higher MMAI scores correlated with shared patterns associated with tumor growth, aggressive disease, and distant cancer spread.

Risk scores at the treatment decision

• Hormone therapy: In Australia’s GenesisCare-led ASTuTE trial, MMAI profiles prompted clinicians and patients to reconsider short-term androgen deprivation therapy in both directions. They avoided hormone therapy when biological risk did not warrant it and recommended it when testing indicated likely benefit.
• Radiation coverage: In India’s POP-RT trial, whole-pelvis radiation was associated with reduced distant cancer spread among patients classified as high MMAI risk. Intermediate-MMAI-risk patients did not show a similar benefit. The analysis was described as the platform’s first clinical validation in a South Asian population.